PONV stands for postoperative nausea and vomiting in adults, which affects roughly 16 million patients annually in the U.S. Enduring surgery is hard enough, and no one should have to deal with nausea and vomiting on top of it. Thankfully, a recent Medscape article discussed a new option to treat PONV. The FDA just approved amisulpride injection, aka Barhemsys from Acacia Pharma, which is the first and only green-lit antiemetic intended to treat PONV. Acacia expects to launch the new injection in the second half of 2020.
Quick Hits: FDA Approves Anti-Nausea Post-Op Injection
16 million Americans suffer from post-op nausea and vomiting each year.
Mar 6, 2020
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
